您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Imiquimod maleate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Imiquimod maleate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Imiquimod maleate图片
CAS NO:896106-16-4
规格:≥98%
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍

Imiquimod maleate (TMX101; R837; S26308; Zyclara; Aldara), the maleate salt of imiquimod, is an immune response modifier acting as an agonist of the TLR7 (toll-like receptor 7). Imiquimod has been approved to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. Scientists at 3M's pharmaceuticals division discovered the drug and 3M obtained the first FDA approval in 1997 under the brand name of Aldara. As of 2015, imiquimod is generic and is available worldwide under many brands. Imiquimod signals to the innate arm of the immune system through the TLR7, commonly involved in pathogen recognition. Cells activated by imiquimod via TLR-7 secrete cytokines such as interferon-α (INF-α), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Imiquimod has been studied in combination with pembrolizumab for treating stage IIIB-IV melanoma.

纯度:≥98%

CAS:896106-16-4